Busulfan, melphalan and carfilzomib high-dose chemotherapy and autologous haematopoietic stem cell transplantation in multiple myeloma.
autologous stem cell transplant
bmt
carfilzomib
high dose therapy
multiple myeloma
myeloma
protease inhibitors
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
04 Jan 2024
04 Jan 2024
Historique:
revised:
15
12
2023
received:
28
10
2023
accepted:
19
12
2023
medline:
5
1
2024
pubmed:
5
1
2024
entrez:
4
1
2024
Statut:
aheadofprint
Résumé
The standard of care for fit, newly diagnosed multiple myeloma patients includes induction therapy followed by consolidative high-dose chemotherapy with melphalan and autologous stem cell transplant (AHSCT). Intensified preparative regimens, such as busulfan and melphalan (BuMel), have shown promise to lengthen progression-free survival (PFS). We previously reported that the addition of bortezomib to BuMel improved PFS compared to melphalan alone in CIBMTR-matched controls. We now integrate the second-generation protease inhibitor, carfilzomib, before and after BuMel (BuMelCar) in a phase I/II trial with carfilzomib. Patients with NDMM, relapsed/refractory MM (RRMM) and those failing prior AHSCT were eligible. Primary end-points were safety and tolerability. Secondary end-points included minimal residual disease negativity rates, PFS and OS. The study enrolled 19 patients. 73% were high risk either due to R-ISS III status, adverse genetics or relapsed after prior AHSCT. The maximum tolerated dose (MTD) of carfilzomib was determined to be 36 mg/m
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
Mina R, Musto P, Rota-Scalabrini D, Paris L, Gamberi B, Palmas A, et al. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial. Lancet Oncol. 2023;24(1):64-76. https://doi.org/10.1016/S1470-2045(22)00693-3
Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136(8):936-945. https://doi.org/10.1182/blood.2020005288
Costa LJ, Zhang MJ, Zhong X, Dispenzieri A, Lonial S, Krishnan A, et al. Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biol Blood Marrow Transplant. 2013;19(11):1615-1624. https://doi.org/10.1016/j.bbmt.2013.08.002
Gao F, Lin M-S, You J-S, Zhang M-Y, Cheng L, Lin K, et al. Long-term outcomes of busulfan plus melphalan-based versus melphalan 200 mg/m2 conditioning regimens for autologous hematopoietic stem cell transplantation in patients with multiple myeloma: a systematic review and meta-analysis. Cancer Cell Int. 2021;21(1):601. https://doi.org/10.1186/s12935-021-02313-z
Solomon SR, Brown S, Shegda N, Jackson KC, Zhang X, Bashey A, et al. High-dose bendamustine, etoposide, cytarabine, and melphalan (BeEAM) conditioning before autologous transplantation for patients with multiple myeloma. Transplant Cell Ther. 2022;28(8):486.e1-486.e7. https://doi.org/10.1016/j.jtct.2022.05.022
Song GY, Jung SH, Kim JS, Eom HS, Moon JH, Yhim HY, et al. Busulfan and thiotepa as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma: a study of the Korean multiple myeloma working party (KMMWP-1801 study). Front Oncologia. 2022;12:959949. https://doi.org/10.3389/fonc.2022.959949
Bashir Q, Thall PF, Milton DR, Fox PS, Kawedia JD, Kebriaei P, et al. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Lancet Haematol. 2019;6(5):e266-e275. https://doi.org/10.1016/S2352-3026(19)30023-7
Park S, Shin DY, Hong J, Kim I, Koh Y, Byun JM, et al. Busulfan plus melphalan versus melphalan alone conditioning regimen after bortezomib based triplet induction chemotherapy for patients with newly diagnosed multiple myeloma. Ther Adv Hematol. 2021;12:20406207211012985. https://doi.org/10.1177/20406207211012985
Blanes M, Lorenzo JI, Ribas P, Jiménez A, González JD, Cejalvo MJ, et al. Intravenous busulfan plus melphalan versus melphalan alone as conditioning regimen for patients with multiple myeloma. Ann Hematol. 2019;98(8):2013-2015. https://doi.org/10.1007/s00277-019-03663-5
Song GY, Jung SH, Lee JJ, Kim JS, Min CK, Kim K, et al. Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis. Leuk Lymphoma. 2020;61(11):2714-2721. https://doi.org/10.1080/10428194.2020.1783448
Hagen P, D'Souza A, Hari P, Davila O, Zhang MJ, Vesole DH, et al. Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: long term follow up of a novel high dose regimen. Leuk Lymphoma. 2020;61(14):3484-3492. https://doi.org/10.1080/10428194.2020.1811275
Blazar BR, Weisdorf DJ, DeFor T, Goldman A, Braun T, Silver S, et al. Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood. 2006;108(9):3216-3222. https://doi.org/10.1182/blood-2006-04-017780
Blijlevens N, de Château M, Krivan G, Rabitsch W, Szomor A, Pytlik R, et al. In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient's burden. Bone Marrow Transplant. 2013;48(7):966-971. https://doi.org/10.1038/bmt.2012.257
Barta SK, Jain R, Mazumder A, Carter J, Almanzar L, Browne R, et al. Pharmacokinetics-directed intravenous busulfan combined with high-dose melphalan and bortezomib as a conditioning regimen for patients with multiple myeloma. Clin Lymphoma Myeloma Leuk. 2017;17(10):650-657. https://doi.org/10.1016/j.clml.2017.06.005
Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003;101(6):2377-2380. https://doi.org/10.1182/blood-2002-06-1768
Lonial S, Kaufman J, Tighiouart M, Nooka A, Langston AA, Heffner LT, et al. A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study. Clin Cancer Res. 2010;16(20):5079-5086. https://doi.org/10.1158/1078-0432.CCR-10-1662
Roussel M, Lauwers-Cances V, Macro M, Leleu X, Royer B, Hulin C, et al. Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study. Blood. 2022;139(18):2747-2757. https://doi.org/10.1182/blood.2021014635
Rodriguez TE, Hari P, Stiff PJ, Smith SE, Sterrenberg D, Vesole DH. Busulfan, melphalan, and bortezomib versus high-dose melphalan as a conditioning regimen for autologous hematopoietic stem cell transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2016;22(8):1391-1396. https://doi.org/10.1016/j.bbmt.2016.03.021
Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782-1791. https://doi.org/10.1056/NEJMoa1114138
van de Donk NW. Carfilzomib versus bortezomib: no longer an ENDEAVOR. Lancet Oncol. 2017;18(10):1288-1290. https://doi.org/10.1016/S1470-2045(17)30613-7
Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27-38. https://doi.org/10.1016/S1470-2045(15)00464-7
Harvey RD. Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib. Clin Pharmacol. 2014;6:87-96. https://doi.org/10.2147/CPAA.S62512
Costa LJ, Landau HJ, Chhabra S, Hari P, Innis-Shelton R, Godby KN, et al. Phase 1/2 trial of carfilzomib plus high-dose melphalan preparative regimen for salvage autologous hematopoietic cell transplantation followed by maintenance carfilzomib in patients with relapsed/refractory multiple myeloma. Biol Blood Marrow Transplant. 2018;24(7):1379-1385. https://doi.org/10.1016/j.bbmt.2018.01.036
Hayman S, LaPlant B, Buadi F, Asmus EJ, Kapoor P, Lacy M, et al. Phase 1/2 trial of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL). Biol Blood Marrow Transplant. 2019;25(3):S30.
Carflizomib [package insert]. Thousand Oaks, CA: Amgen, Inc; 2012 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202714s025lbl.pdf
Usmani SZ, Quach H, Mateos M-V, Landgren O, Leleu X, Siegel D, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomized, multicentre, open-label, phase 3 study. Lancet Oncol. 2022;23(1):65-76.
Madden T, de Lima M, Thapar N, Nguyen J, Roberson S, Couriel D, et al. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. Biol Blood Marrow Transplant. 2007;13:56-64.
Durie BGM, Harousseau J-L, Miguel JS, Bladé J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467-1473. https://doi.org/10.1038/sj.leu.2404284
Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, García-Sánchez O, Böttcher S, et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31(10):2094-2103. https://doi.org/10.1038/leu.2017.29
Perrot A, Lauwers-Cances V, Corre J, Robillard N, Hulin C, Chretien M-L, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018;132(23):2456-2464. https://doi.org/10.1182/blood-2018-06-858613
Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(5):548-567. https://doi.org/10.1002/ajh.25791
Sada S, Benini L, Pavan C, Favalli MN, Mansueto G, Capelli P, et al. Ischemic colitis sustained by sickle cell trait in young adult patient. Am J Gastroenterol. 2005;100(12):2818-2821. https://doi.org/10.1111/j.1572-0241.2005.00309_7.x
Grazziutti ML, Dong L, Miceli MH, Krishna SG, Kiwan E, Syed N, et al. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model. Bone Marrow Transplant. 2006;38(7):501-506. https://doi.org/10.1038/sj.bmt.1705471
Chakraborty R, Muchtar E, Kumar SK, Jevremovic D, Buadi FK, Dingli D, et al. Impact of post-transplant response and minimal residual disease on survival in myeloma with high-risk cytogenetics. Biol Blood Marrow Transplant. 2017;23(4):598-605. https://doi.org/10.1016/j.bbmt.2017.01.076